GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Leap Therapeutics Inc.
Leap Therapeutics is an oncology company. Its stock price is a bet on the success of its lead drug candidate. Its price is volatile and driven by news of clinical trials and partnerships that help fund its expensive development.
Share prices of companies in the market segment - Oncology immuno-therapy
Leap Therapeutics develops targeted and immuno-oncology therapies for cancer treatment. Its key drugs target tumors by activating the immune system. We've categorized it as "Immuno-Oncology," and the chart below illustrates the dynamics of this cutting-edge biotech sector.
Broad Market Index - GURU.Markets
Leap Therapeutics is an oncology company developing targeted and immunotherapeutic drugs. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Leap shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
LPTX - Daily change in the company's share price Leap Therapeutics Inc.
Leap Therapeutics, Inc.'s daily stock price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about the clinical trials of its oncology drugs.
Daily change in the price of a set of shares in a market segment - Oncology immuno-therapy
Leap Therapeutics, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with LPTX's dynamics, which depend on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Leap Therapeutics is a biotech company developing cancer immunotherapy drugs. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Leap Therapeutics Inc.
Leap Therapeutics, Inc.'s year-to-date performance is a story about its targeted oncology drug development. Its 12-month market cap is entirely dependent on clinical trial data for its DKN-01 antibody. Success in gastric and colorectal cancer research could be a fundamental breakthrough for the company and a validation of its scientific strategy.
Annual dynamics of market capitalization of the market segment - Oncology immuno-therapy
Leap Therapeutics, Inc. is a clinical-stage biotech company developing drugs for the treatment of cancer. Its stock performance is entirely dependent on the results of clinical trials. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Leap Therapeutics, an immuno-oncology company, exemplifies the binary nature of biotech investing. Its shares move not in sync with the market, but with the release of clinical trial data. Positive results lead to sharp outperformance, while negative results lead to a crash.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Leap Therapeutics Inc.
Leap Therapeutics is a clinical-stage oncology company. Its monthly performance directly reflects news from its clinical trials. Any data on its lead drug, DKN-01, triggers an immediate and strong investor reaction, typical of biotech.
Monthly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Leap Therapeutics is a biotech company developing targeted and immuno-oncology drugs for the treatment of cancer. Its lead candidate is aimed at overcoming resistance to standard therapy. The graph below shows the dynamics of the biotech sector, where combating tumor resistance is a key challenge.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Leap Therapeutics is a biotech company developing cancer treatments. Its stock moves not in sync with the market, but rather based on clinical trial results. The success of a single drug can trigger explosive growth, completely ignoring external market conditions.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Leap Therapeutics Inc.
Leap Therapeutics is an oncology company developing targeted therapies and immunotherapies. Its weekly stock price is volatile and depends on the results of clinical trials of its key drug candidates.
Weekly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Leap Therapeutics is a biotech company focused on immuno-oncology. For them, clinical trial news is everything. This chart clearly demonstrates whether the sharp weekly stock price swings reflect unique successes or general optimism or pessimism in the sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Leap Therapeutics is another biotech company whose stock exists in its own universe, reacting to clinical trial data. The chart clearly demonstrates how its weekly performance is isolated from general market fluctuations, following its own unique scientific trajectory.
Market capitalization of the company, segment and market as a whole
LPTX - Market capitalization of the company Leap Therapeutics Inc.
The Leap Therapeutics chart is a curve of hopes in immuno-oncology. Its market cap reflects investor confidence in the company's lead drug candidate, designed to treat gastrointestinal cancer. Its performance is a direct response to clinical trial results and partnerships.
LPTX - Share of the company's market capitalization Leap Therapeutics Inc. within the market segment - Oncology immuno-therapy
Leap Therapeutics is a biopharmaceutical company developing targeted and immuno-oncology drugs. In this segment, its market capitalization reflects the potential of its leading drug candidates. The dynamics of this metric are a sensitive barometer of news about clinical trials, partnerships, and regulatory decisions.
Market capitalization of the market segment - Oncology immuno-therapy
Leap Therapeutics develops targeted and immuno-oncology drugs. How big is this arena? The chart below shows the pulse of the entire immuno-oncology sector. Its high volatility reflects both the enormous hopes for new cancer treatments and the high risk of clinical failure.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Leap Therapeutics chart shows how the market is pricing in the development of a new generation of anti-cancer antibodies. Its market cap is a bet on the success of its key drug in the treatment of stomach and esophageal cancer. The chart dynamics visualize how clinical trial data determines the biotech company's fate.
Book value capitalization of the company, segment and market as a whole
LPTX - Book value capitalization of the company Leap Therapeutics Inc.
The book value of Leap Therapeutics, an immuno-oncology company, is its tangible asset base, consisting of the rights to its drug candidates and financial reserves for clinical trials. The chart below shows how this critical scientific and financial foundation has evolved.
LPTX - Share of the company's book capitalization Leap Therapeutics Inc. within the market segment - Oncology immuno-therapy
Leap Therapeutics, Inc. is an immuno-oncology company whose tangible assets are the research laboratories where its cancer antibodies are developed. These R&D centers are its physical base for innovation. The chart shows the percentage of this specialized scientific infrastructure the company controls.
Market segment balance sheet capitalization - Oncology immuno-therapy
Leap Therapeutics is an oncology company. Pharmaceuticals, as the chart shows, are both knowledge- and capital-intensive. Leap focuses on drug development, and its capital is intellectual property and R&D infrastructure for clinical trials.
Book value of all companies included in the broad market index - GURU.Markets
Leap Therapeutics' assets are not factories, but capital allocated to clinical trials of its lead antibody candidate for the treatment of stomach cancer and other oncological diseases. Its book value reflects its financial resources for this development.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Leap Therapeutics Inc.
Leap Therapeutics is a biotech company developing antibodies for cancer treatment. Its market capitalization is the valuation of its lead drug, DKN-01. The chart shows how its stock price moves based on news about clinical trials and partnerships.
Market to book capitalization ratio in a market segment - Oncology immuno-therapy
Leap Therapeutics is a biotech company developing targeted and immuno-oncology drugs. Its valuation is dependent on clinical trial results. The chart shows how investors view the prospects of its development pipeline relative to its current tangible assets.
Market to book capitalization ratio for the market as a whole
Leap Therapeutics is an immuno-oncology company. Its market capitalization reflects the potential value of its drugs if successful, not its current assets. This chart illustrates how valuation in biotech is a bet on the future, where intangible assets (IP) are valued disproportionately higher than tangible ones.
Debts of the company, segment and market as a whole
LPTX - Company debts Leap Therapeutics Inc.
Leap Therapeutics is a biotech company focused on developing targeted and immuno-oncology drugs. Conducting multiple clinical trials simultaneously requires a constant influx of capital. This chart shows how the company manages its financial needs to support its pipeline of drug candidates at various stages of development.
Market segment debts - Oncology immuno-therapy
Leap Therapeutics is a clinical-stage oncology company developing targeted and immunotherapies. Its future depends on the results of clinical trials of its lead drug candidates. This chart shows its cash reserves and how long it can fund its expensive research without additional capital.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Leap Therapeutics Inc.
Leap Therapeutics is a biopharmaceutical company focused on immuno-oncology. This chart shows its financial structure. Debt during clinical trials is a significant burden for the company, diverting resources from its primary goal—successfully completing research and bringing the drug to market.
Market segment debt to market segment book capitalization - Oncology immuno-therapy
Leap Therapeutics is a biotech company developing targeted and immuno-oncology drugs. Its success depends on the results of clinical trials. The chart shows the overall debt burden in the pharmaceutical industry, providing investors with context for assessing Leap's financial strategy on its long and risky path to potential drug approval.
Debt to book value of all companies in the market
Leap Therapeutics, Inc. is a biopharmaceutical company developing targeted therapies for cancer treatment. While in clinical trials, it has no stable revenue. This chart shows that the debt market is virtually closed to such companies, and their ability to continue research depends on raising equity capital.
P/E of the company, segment and market as a whole
P/E - Leap Therapeutics Inc.
For Leap Therapeutics, a clinical-stage immuno-oncology company, P/E is not a meaningful metric. It has no products or revenues. Its valuation on this chart is arbitrary. The company's true value is determined by investors' faith in the potential of its scientific developments to create a new generation of cancer drugs.
P/E of the market segment - Oncology immuno-therapy
Leap Therapeutics is a biopharmaceutical company developing targeted and immuno-oncology drugs for the treatment of cancer. This chart shows the average valuation for the sector, providing investors with context for assessing Leap Therapeutics' scientific pipeline and potential.
P/E of the market as a whole
Leap Therapeutics is a biotech company developing targeted and immuno-oncology therapies. Its valuation is a pure bet on the success of its clinical programs. Overall market sentiment, reflected in this chart, is completely irrelevant. The company's fate depends on the effectiveness of its experimental drugs.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Leap Therapeutics Inc.
Leap Therapeutics is a biotech company developing targeted and immuno-oncology drugs. This chart reflects investor expectations for the clinical trials of its lead antibody, DKN-01. The company's valuation is based on the projected future success of its drugs in the treatment of gastrointestinal and gynecologic cancers.
%20P%2FE%20Leap%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Leap-Therapeutics-Inc.&v=1772682891434 "Chart of the company's future (projected) P/E Leap Therapeutics Inc.")
Future (projected) P/E of the market segment - Oncology immuno-therapy
Leap Therapeutics is a biopharmaceutical company focused on developing targeted and immuno-oncology therapies. Its valuation relative to other oncology biotechs reflects investor sentiment on its lead drug, DKN-01, demonstrating the market's confidence in its potential to treat various cancers.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-immuno-therapy&v=1772682891534 "Future (projected) P/E graph of the market segment - Oncology immuno-therapy")
Future (projected) P/E of the market as a whole
Leap Therapeutics is a biopharmaceutical company developing targeted and immuno-oncology drugs. Its key drug targets gastric cancer and other solid tumors. This chart shows investors' overall risk appetite, a key factor in evaluating clinical-stage biotechs whose value depends on the success of their research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772682891572 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Leap Therapeutics Inc.
Leap Therapeutics is a clinical-stage biotech developing antibodies for cancer treatment. The financial metrics shown in the chart primarily reflect clinical trial costs. Positive data on its key drug, DKN-01, is the company's primary driver.
Profit of companies in the market segment - Oncology immuno-therapy
Leap Therapeutics is an oncology company developing targeted and immunotherapeutic drugs. This chart reflects the financial health of the immuno-oncology sector. It shows how competitive it is and the chances of small biotech companies achieving commercial success in one of the hottest areas of pharmaceuticals.
Overall market profit
Leap Therapeutics is a biopharmaceutical company specializing in immuno-oncology. It develops drugs that help the immune system fight cancer. Its prospects, like those of other companies in the sector, are determined by the results of clinical trials rather than the overall economic situation, as reflected in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Leap Therapeutics Inc.
Leap Therapeutics is a biotech company focused on developing targeted and immuno-oncology drugs. Its future revenue projections depend on clinical trial results and potential partnerships. This chart reflects analysts' assessments of the prospects of its leading drug candidates for the treatment of various cancers.
%20profit%20of%20the%20company%20Leap%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Leap-Therapeutics-Inc.&v=1772682891663 "Graph of future (projected) profit of the company Leap Therapeutics Inc.")
Future (predicted) profit of companies in the market segment - Oncology immuno-therapy
Leap Therapeutics is a biotech company developing targeted and immuno-oncology antibodies for cancer treatment. Their lead drug is aimed at overcoming tumor resistance to chemotherapy. This chart shows forecasts for the immunotherapy segment. It helps assess the potential contribution of new approaches to treating difficult-to-treat cancers to industry growth.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-immuno-therapy&v=1772682891712 "Graph of future (predicted) profits of companies in a market segment - Oncology immuno-therapy")
Future (predicted) profit of the market as a whole
For Leap Therapeutics, an oncology company in clinical development, this chart is an indicator of the availability of venture capital. An optimistic economic outlook facilitates raising funding to continue development. A negative trend, on the other hand, could make it more difficult to find investors.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772682891758 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Leap Therapeutics Inc.
Leap Therapeutics is a biotech company developing targeted drugs for cancer treatment. This chart, with minimal revenue, illustrates the value investors place on its clinical programs and future sales potential.
P/S market segment - Oncology immuno-therapy
Leap Therapeutics is a biopharmaceutical company developing targeted and immuno-oncology drugs for the treatment of cancer. This chart shows the average valuation in the immunotherapy sector. It helps understand how investors view Leap's pipeline and its potential for combination with other treatments to achieve better patient outcomes.
P/S of the market as a whole
Leap Therapeutics, Inc. is a biopharmaceutical company developing targeted and immuno-oncology therapies. Its lead drug candidate targets gastric and esophageal cancer. Future revenue is dependent on the success of clinical trials. This chart provides context for assessing the risks and potential of oncology biotech.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Leap Therapeutics Inc.
Leap Therapeutics is a biotech company developing antibodies for cancer treatment. Future revenue depends on the success of clinical trials of its lead drug, DKN-01. This chart shows how investors assess the chances of success of this drug in various combinations and its commercial potential.
%20P%2FS%20Leap%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Leap-Therapeutics-Inc.&v=1772682891871 "The graph of the company's future (projected) P/S Leap Therapeutics Inc.")
Future (projected) P/S of the market segment - Oncology immuno-therapy
Leap Therapeutics is a biopharmaceutical company developing targeted and immuno-oncology drugs for the treatment of cancer. Its lead candidate targets a specific protein that plays a role in tumor growth. This chart shows how investors view the potential of its developments compared to other oncology companies.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-immuno-therapy&v=1772682891929 "Future (projected) P/S market segment graph - Oncology immuno-therapy")
Future (projected) P/S of the market as a whole
This chart shows general expectations for the immuno-oncology market. For Leap Therapeutics, a biotech company developing targeted cancer drugs, this is an indicator of the investment climate. Market optimism allows it to attract capital for clinical trials targeting key tumor cell signaling pathways.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772682891937 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Leap Therapeutics Inc.
Leap Therapeutics is a biopharmaceutical company developing targeted and immuno-oncology therapies. Its lead candidate targets gastrointestinal cancer. This chart reflects revenue from licensing agreements. Future revenue growth will depend on the success of clinical trials and the commercialization of its drug candidates.
Sales of companies in the market segment - Oncology immuno-therapy
Leap Therapeutics is a biotech company developing targeted and immuno-oncology drugs. This chart shows the growth of the cancer immunotherapy market. Leap Therapeutics focuses on new biological targets to overcome resistance to existing treatments, placing it at the forefront of the fight against cancer.
Overall market sales
Leap Therapeutics, Inc. is a biopharmaceutical company focused on developing targeted immuno-oncology drugs. Its market capitalization is dependent on clinical trial results. The overall economic situation, reflected in this chart, influences the investment climate in the biotech sector, determining the availability of financing.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Leap Therapeutics Inc.
Leap Therapeutics is a biopharmaceutical company developing targeted and immuno-oncology drugs for the treatment of cancer. Its lead candidate is aimed at treating gastric and esophageal cancer. The company's future depends on the results of its key clinical trials. This chart reflects analysts' assessment of the commercial potential of the company's lead drug.
%20sales%20of%20the%20company%20Leap%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Leap-Therapeutics-Inc.&v=1772682892036 "Schedule of future (projected) sales of the company Leap Therapeutics Inc.")
Future (projected) sales of companies in the market segment - Oncology immuno-therapy
Leap Therapeutics is a biopharmaceutical company developing immuno-oncology drugs. This chart reflects expectations for the entire cancer immunotherapy sector. It shows analysts' confidence in the potential of new combinations and approaches to activating the immune system to fight tumors.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-immuno-therapy&v=1772682892039 "Schedule of future (projected) sales of companies in the market segment - Oncology immuno-therapy")
Future (projected) sales of the market as a whole
Leap Therapeutics, Inc. is a biopharmaceutical company developing targeted and immuno-oncology therapies. Its value is driven by progress in clinical trials. The overall economic environment, reflected in this chart, influences investor risk appetite, which is important for funding biotech companies working on breakthrough treatments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772682892113 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Leap Therapeutics Inc.
Leap Therapeutics is a biotech company developing targeted and immuno-oncology drugs. This chart reflects the financial picture at the clinical trial stage. Negative values represent necessary research expenses designed to prove the efficacy of its candidates and lead to their commercialization.
Market segment marginality - Oncology immuno-therapy
Leap Therapeutics is a biopharmaceutical company specializing in cancer treatment development. For a company with products in clinical trials, this chart is important as an indicator of potential. It reflects the average profitability in the oncology sector, which Leap aims to achieve if its drugs are successfully brought to market.
Market marginality as a whole
Leap Therapeutics is a biopharmaceutical company developing targeted and immuno-oncology therapies. This total market profitability graph is not directly relevant to the company. Its future depends on the results of clinical trials and strategic partnerships. The company's potential lies in creating new standards of cancer treatment.
Employees in the company, segment and market as a whole
Number of employees in the company Leap Therapeutics Inc.
Leap Therapeutics is a biotech company focused on developing targeted and immuno-oncology drugs. This graph shows a small team managing the clinical trials of its candidates. Their size is typical for a company whose strategy is based on partnerships with major pharma.
Share of the company's employees Leap Therapeutics Inc. within the market segment - Oncology immuno-therapy
Leap Therapeutics develops antibodies for the treatment of oncology. In this highly competitive biotech field, the scientific team is the company's most valuable asset. This metric reflects the percentage of leading oncologists and antibody specialists the company attracts, demonstrating its focus and concentration of talent in the development of targeted therapies.
Number of employees in the market segment - Oncology immuno-therapy
Leap Therapeutics is a biopharmaceutical company developing targeted and immuno-oncology drugs. Its focus on specific biomarkers enables the creation of personalized treatments. This graph illustrates how medicine is becoming increasingly precise, requiring in-depth scientific research and the involvement of highly qualified oncologists.
Number of employees in the market as a whole
Leap Therapeutics, an immuno-oncology company, is part of the global race for cancer cures. This chart illustrates the scale of the US labor market, a global hub for biotech innovation. Companies like Leap attract the best minds from around the world, maintaining the country's status as a leader in science-intensive industries.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Leap Therapeutics Inc. (LPTX)
Leap Therapeutics is a biotech company specializing in oncology. This chart is a classic example of intellectual capital valuation. The company's value is based on market expectations for its drug candidates, particularly DKN-01. The chart shows the high future value the market attributes to these developments, per scientist.
%20of%20the%20company%20Leap%20Therapeutics%20Inc.%20(LPTX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Leap-Therapeutics-Inc.-LPTX&v=1772682892309 "Chart of market capitalization per employee (in thousands of dollars) of the company Leap Therapeutics Inc. (LPTX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Leap Therapeutics is a biotech company focused on immuno-oncology. Its market capitalization is a measure of the potential of its clinical developments. This chart shows the enormous value the market can attribute to each scientist working on a potential blockbuster. It compares investor faith in their scientific team.
%20by%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-immuno-therapy&v=1772682892322 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology immuno-therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Leap Therapeutics, Inc. is a biopharmaceutical company developing targeted and immuno-oncology therapies. This chart reflects the average market value assigned to one employee, highlighting the high valuation of its research in oncology.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772682892357 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Leap Therapeutics Inc. (LPTX)
Leap Therapeutics is a clinical-stage biotech focused on oncology. The company has no commercial products. This chart shows the net loss per employee. It reflects not inefficiency, but the company's "bet"—how much it invests in each scientist to conduct research.
%20Chart%20Leap%20Therapeutics%20Inc.%20(LPTX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Leap-Therapeutics-Inc.-LPTX&v=1772682892371 "Company Profit Per Employee (in thousands of dollars) Chart Leap Therapeutics Inc. (LPTX)")
Profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Leap Therapeutics is a biopharmaceutical company developing targeted and immuno-oncology drugs. Its business is entirely focused on clinical research. For such companies, this chart is an indicator of R&D expenditures per employee. Negative values are typical and reflect the investment in the scientific team working on the development of future blockbusters.
%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-immuno-therapy&v=1772682892407 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Leap Therapeutics (LPTX) is a clinical-stage biotech developing targeted therapies (antibodies) for cancer, specifically DKK1 (for stomach and esophageal cancer). This is an R&D business. This chart shows the market average dollar return per employee. For LPTX (which is not yet profitable), this is a benchmark: in biotech, IP can significantly exceed this average.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772682892422 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Leap Therapeutics Inc. (LPTX)
Leap Therapeutics is a biopharmaceutical company specializing in immuno-oncology. For a clinical-stage company, this graph is a progress indicator. Its future growth will depend on the success of clinical trials and the ability to commercialize its cancer treatments.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Leap-Therapeutics-Inc.-LPTX&v=1772682892429 "Sales chart per company employee Leap Therapeutics Inc. (LPTX)")
Sales per employee in the market segment - Oncology immuno-therapy
Leap Therapeutics is a clinical-stage biotech company focused on developing targeted therapies for cancer. Revenue is not yet available. This chart shows the average revenue per employee in the segment, which serves as a benchmark for commercial pharmaceutical companies. It provides context for assessing the effectiveness of Leap's staff.
Sales per employee for the market as a whole
Leap Therapeutics is a clinical-stage biotech company specializing in immuno-oncology. The company has no approved products and, consequently, no commercial revenue. This metric is currently irrelevant. The R&D team is fully focused on successfully completing clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company Leap Therapeutics Inc. (LPTX)
Leap Therapeutics is a biotech whose fate hinges on a single drug (DKK1), which they are testing in combination for cancer treatment. It's a risky "all-in" strategy. This chart shows the number of bears betting that their drug candidate will fail in clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Leap-Therapeutics-Inc.-LPTX&v=1772682892516 "Short Shares Chart for the Company Leap Therapeutics Inc. (LPTX)")
Shares shorted by market segment - Oncology immuno-therapy
Leap Therapeutics, Inc. is a biopharmaceutical company developing antibodies for the treatment of oncology, particularly gastrointestinal cancer. This chart reflects the total short position in the immuno-oncology sector. High values indicate general investor skepticism about the success of clinical trials in this highly competitive field.
Shares shorted by the overall market
Leap Therapeutics is a biotech company focused on immuno-oncology. This chart illustrates the overall market pessimism. For companies burning through cash on R&D, rising fears mean the window for raising capital is closing. Investors are unwilling to take risks, fearing failure in clinical trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Leap Therapeutics Inc. (LPTX)
This chart for Leap Therapeutics is an indicator of binary bets in oncology. The company is betting on its drug DKN-01 for gastrointestinal cancer. "Overbought" levels (above 70) arise from positive Phase 2 data, especially in combination with other drugs. A failure in a key trial or doubts about efficacy will immediately crash the oscillator (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Leap-Therapeutics-Inc.-LPTX&v=1772682892605 "RSI 14 indicator chart for the company's stock Leap Therapeutics Inc. (LPTX)")
RSI 14 Market Segment - Oncology immuno-therapy
Leap Therapeutics (LPTX) is a biotech company focused on cancer (immuno-oncology). The oncology immuno-therapy (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand whether LPTX's growth is due to its R&D or whether the entire biotech sector is simply overheated.
RSI 14 for the overall market
Leap Therapeutics (LPTX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast LPTX (Leap Therapeutics Inc.)
Leap Therapeutics is a biotech company developing cancer treatments. Their lead candidate (DKN-01) targets gastrointestinal tumors. This chart shows the analysts' average 12-month forecast, representing their collective bet that DKN-01 will be successful in clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-LPTX-Leap-Therapeutics-Inc.&v=1772682892691 "A chart showing analyst consensus forecasts for the expected stock price. LPTX (Leap Therapeutics Inc.)")
The difference between the consensus estimate and the actual stock price LPTX (Leap Therapeutics Inc.)
Leap Therapeutics is an oncology company whose key drug (DKN-01) targets DKK1, which should help the immune system attack cancer. This chart shows the difference between the market valuation and the consensus estimate. It reveals whether experts believe this targeted immunotherapy will be clinically successful.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-LPTX-Leap-Therapeutics-Inc.&v=1772682892739 "A chart showing the difference between the consensus forecast and the actual stock price. LPTX (Leap Therapeutics Inc.)")
Analyst consensus forecast for stock prices by market segment - Oncology immuno-therapy
Leap Therapeutics is a clinical-stage biotech focused on the R&D of targeted antibodies for cancer treatment. This chart reflects analyst expectations for the entire immunotherapy sector. It shows whether experts believe junior biotechs are successful or consider the sector overheated.
Analysts' consensus forecast for the overall market share price
Leap Therapeutics is a biotech company specializing in the development of antibodies (immunotherapy) for cancer treatment. This chart reflects the overall market "risk appetite." For Leap, a high-risk clinical-stage company, overall market optimism (risk appetite) is critical to attracting the capital needed to fund long-term clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Leap Therapeutics Inc.
Leap Therapeutics is a biotech R&D company focused on immuno-oncology. Their flagship drug (DKK1) is an antibody designed to unleash the immune system to attack complex tumors (stomach, intestine). This chart is a clear indicator of their faith in R&D. It reflects their (highly risky) progress in clinical trials and their partnerships (like with BeiGene).
AKIMA Market Segment Index - Oncology immuno-therapy
Leap Therapeutics (LPTX) is an oncology company developing targeted and immunotherapeutic drugs. Their lead candidate (DKN-01) targets the DKK1 signaling pathway, which plays a role in many types of cancer. The chart shows the segment average index, helping investors assess how LPTX's risks and potential compare to the sector average.
The AKIM Index for the overall market
Leap Therapeutics is an oncology company developing monoclonal antibodies (DKN-01) for the treatment of stomach cancer and other tumors. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this clinical-stage research story compares to overall economic trends.
